340B Providers Lose their Biggest GOP Ally in U.S. House

U.S. Rep. David McKinley (R-WA) gestures during hearing
U.S. Rep. David McKinley (R-W.Va.) lost his GOP primary election this week. It's a huge blow for 340B entities that have relied on his help in Congress for years.

In a major blow to the 340B provider community, U.S. Rep. David McKinley, the leading voice for the 340B program in the House Republican caucus, was defeated Tuesday in the West Virginia Republican primary. McKinley will remain in office until

Read More »

Drug Makers Ask Michigan Lawmakers to Erase Section from New 340B State Law

Copy of State of Michigan bill no. 4351
Michigan 340B hospitals say drug manufacturers are lobbying state lawmakers to erase language from a new state law that the hospitals say stops the drug makers from imposing claims submission requirements as a condition for 340B pricing.

Drug manufacturers are asking Michigan state legislators to erase language in a new state law that Michigan hospitals say bars the companies from withholding 340B pricing if a covered entity refuses to hand over its contract pharmacy claims data, 340B

Read More »

Letting Pharma Put Strings on 340B is Letting Fox Guard Henhouse, Feds Tell Appeals Courts

Department of Justice sign on a building facade
The DOJ told federal appeals courts in Philadelphia and Washington, D.C., that HHS was right to tell drug manufacturers their conditions on 340B contract pharmacy are illegal and must end.

Letting drug manufacturers put conditions on 340B drug discounts “would be akin to letting the fox guard the henhouse,” the U.S. Justice Department (DOJ) told federal appeals courts in Philadelphia and Washington, D.C., last night in a pair of filings

Read More »

Amgen and GSK Announce Refunds for 340B Overcharges

Enbrel autoinjector product tubes
Amgen is providing refunds for 340B overcharges for four NDCs of its top-selling drug Enbrel during 2016 and 2017.

Drug manufacturer Amgen is providing refunds for overcharges during varying periods over three years on some of its top selling drugs including Enbrel ($4.8 billion in U.S. sales in 2020), Neulasta ($2 billion), Kyprolis ($710 million), Aranesp ($629 million), Epogen

Read More »

Drug Industry-Funded Consumer Group Slams 340B on Conservative News Site

Screenshot of RealClear Health 340B Program story, "340B Program Isn't Working for Patients"
Industry-supported consumer protection group National Consumers League sharply criticized 340B hospitals and contract pharmacies in a recent opinion article for a conservative-leaning news site.

America’s oldest consumer protection group, shunned by some former allies in the labor movement for alleged favoritism toward its corporate donor Amazon, has slammed the 340B program in a commentary for the conservative-leaning news and opinion website RealClearHealth.

“Sadly, as

Read More »

340B Publisher & CEO: 340B Ceiling Price Website Is Welcome Step but Needs Improvement

screenshot of HRSA website ceiling price lookup instructions
340B Report Publisher and CEO Ted Slafsky commends HRSA for its ceiling price website but encourages improvements to the site.

After a nine-year delay, federal officials in April 2019 did as Congress ordered and began posting 340B ceiling prices on a secure website. For the first time, providers enrolled in the 340B program had a tool to help them make

Read More »

Breaking News

HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months

Merck wordmark on building-mounted sign
HRSA told Merck today the company's conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop or Merck could face civil monetary penalties.

The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each instance of

Read More »

Survey: Hospitals’ Losses from 340B Contract Pharmacy Restrictions Ballooned During Q1 2022

Annualized losses due to contract pharmacy restrictions December 2021 vs. March 2022 comparison
340B hospitals' annualized losses due to drug makers contract pharmacy restrictions grew sharply during Q1 2022, a survey found.

The financial impact to 340B hospitals due to drug manufacturers’ restrictions on contract pharmacy more than doubled between December 2021 and March 2022, a new survey shows.

Hospital trade group 340B Health said the median annualized loss of contract pharmacy

Read More »

Fed. Judge Lets 340B Providers Intervene in Closely Watched Contract Pharmacy Lawsuit

Piggott community hospital ambulance
A federal judge is letting Piggott Community Hospital in northeastern Arkansas and Community Health Centers of Arkansas intervene in PhRMA's lawsuit challenging a state law protecting 340B contract pharmacy arrangements.

A federal district judge on Tuesday let Arkansas’ state health center association and a critical access hospital in the state have a role in the drug industry’s lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.

U.S. Senior

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report